Gemvax as

Marianne Klemp Gjertsen

Jon Amund Eriksen

Gustav Gaudernack

Mona Møller

Ingvil Sæterdal

Ingvil Saeterdal

Mona Moller

Stein Sæbøe-Larsen

Gustay Gaudernack

Mona M&oslash;ller

Ingvil S&aelig;terdal

Mona Moeller

Jon Armund Eriksen

Stein Saebo-Larsen

Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.

Peptides

Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.

This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.

Antigenic peptides derived from telomerase

Growing community of inventors

Snaroya, Norway

Marianne Klemp Gjertsen